A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential. To address this, we developed a computational biology modeling (CBM) and digital drug simulation platform that relies on somatic gene mutations and gene CNVs found in malignant cells of individual patients.

Blood Advances 2019 Myelodysplastic Syndrome Acute Myeloid Leukemia